| 证券代码 | XENT.O |
| 证券名称 | Intersect ENT Inc |
| 证券类型 | 美股 |
| 上市场所 | 纳斯达克交易所 |
| 上市板块 | 主板 |
| 发行方式 | 公开发售 |
| 首发上市日 | 2014-07-24 |
| 首发价格(元) | 11 USD |
| 首发数量(股) | 5000000 |
| 首发募资额(元) | 55,000,000.00 USD |
| 首发主承销商 | Piper Jaffray & Co.,J.P. Morgan Securities LLC |
| 货币单位 | USD |
| 公司名称 | Intersect ENT, Inc. |
| 注册地址 | 美国特拉华州 |
| 办公地址 | 1555 Adams Drive, Menlo Park, California, USA |
| 成立日期 | 2003-10 |
| 董事会主席 | Kieran T. Gallahue |
| 公司属地 | United States 美国 |
| 公司网址 | www.intersectent.com |
| 电话 | +1 (650) 641-2100 |
| 传真 | - |
| 公司简介 | Intersect ENT, Inc. is dedicated to transforming the landscape of care for patients with ear, nose and throat conditions. The company’s PROPEL family of dissolvable steroid releasing implants are clinically proven to improve outcomes for chronic sinusitis patients undergoing sinus surgery. In addition, Intersect ENT is continuing to expand its portfolio of products based on the company’s unique localized steroid releasing technology and is committed to broadening patient access to less invasive and more cost effective care. Intersect ENT: Delivering Innovation. Where It’s Needed. |